WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317165
CAS#: 81403-68-1 (Alfuzosin HCl), 81403-80-7(Alfuzosin).
Description: Alfuzosin HCl is a pharmaceutical drug of the alpha-1 blocker class. As an antagonist of the alpha-1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH). Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xat or Xatral, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.
MedKoo Cat#: 317165
Name: Alfuzosin HCl
CAS#: 81403-68-1 (Alfuzosin HCl), 81403-80-7(Alfuzosin).
Chemical Formula: C19H27N5O4
Exact Mass: 389.2063
Molecular Weight: 389.46
Elemental Analysis: C, 58.60; H, 6.99; N, 17.98; O, 16.43
Related CAS #: 81403-68-1 (Alfuzosin HCl) 81403-80-7(Alfuzosin).
Synonym: Alfetim; alfusozine; alfuzosin; alfuzosin hydrochloride; alphuzosine; Benestan; N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; Urion; UroXatral; Xatral
IUPAC/Chemical Name: N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide, monohydrochloride
InChi Key: YTNKWDJILNVLGX-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H27N5O4.ClH/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19;/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23);1H
SMILES Code: O=C(C1OCCC1)NCCCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)C.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 389.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Rudraswamy-Math NR, Gupta VR. Formulation and evaluation of gastroretentive controlled release tablets of alfuzosin hydrochloride. Pak J Pharm Sci. 2015 Nov;28(6):2147-52. PubMed PMID: 26639508.
2: Altın S, Ozan T, İlhan S, İlhan N, Onur R. Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study. Turk J Urol. 2015 Sep;41(3):125-31. doi: 10.5152/tud.2015.89656. PubMed PMID: 26516595; PubMed Central PMCID: PMC4608450.
3: Pattnaik S, Swain K, Rao JV, Varun T, Mallick S. Temperature influencing permeation pattern of alfuzosin: An investigation using DoE. Medicina (Kaunas). 2015;51(4):253-61. doi: 10.1016/j.medici.2015.07.002. Epub 2015 Jul 30. PubMed PMID: 26424191.
4: Ben Rhouma S, H'sairi M, Adbi H, Binous MY, Nouira Y, Ben Raies N, Mosbah AT, Horchani A. [Impact of alfuzosin 10 mg once daily on quality of life in tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia]. Tunis Med. 2015 Mar;93(3):164-9. French. PubMed PMID: 26367405.
5: Liu C, Zeng G, Kang R, Wu W, Li J, Chen K, Wan SP. Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis. PLoS One. 2015 Aug 5;10(8):e0134589. doi: 10.1371/journal.pone.0134589. eCollection 2015. PubMed PMID: 26244843; PubMed Central PMCID: PMC4526635.
6: Liu S, Yu Y, Gao Y, Yang X, Pang Z. Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study. Urolithiasis. 2015 Aug 5. [Epub ahead of print] PubMed PMID: 26242466.
7: Kwon JK, Cho KS, Oh CK, Kang DH, Lee H, Ham WS, Choi YD, Lee JY. The beneficial effect of alpha-blockers for ureteral stent-related discomfort: systematic review and network meta-analysis for alfuzosin versus tamsulosin versus placebo. BMC Urol. 2015 Jun 24;15:55. doi: 10.1186/s12894-015-0050-5. PubMed PMID: 26104313; PubMed Central PMCID: PMC4477492.
8: El Said NO, El Wakeel L, Kamal KM, Morad Ael R. Alfuzosin treatment improves the rate and time for stone expulsion in patients with distal uretral stones: a prospective randomized controlled study. Pharmacotherapy. 2015 May;35(5):470-6. doi: 10.1002/phar.1593. PubMed PMID: 26011140.
9: Gokkaya CS, Aktas BK, Ozden C, Bulut S, Karabakan M, Erkmen AE, Memis A. Flurbiprofen alone and in combination with alfuzosin for the management of lower urinary tract symptoms. Cent European J Urol. 2015;68(1):51-6. doi: 10.5173/ceju.2015.01.500. Epub 2015 Feb 9. PubMed PMID: 25918641; PubMed Central PMCID: PMC4408396.
10: Cicek T, Gokturk HS, Unler GK. Acute hepatocellular drug induced liver injury probably by alfuzosin. Case Rep Urol. 2015;2015:101062. doi: 10.1155/2015/101062. Epub 2015 Feb 22. PubMed PMID: 25793140; PubMed Central PMCID: PMC4352498.
